By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



540 – 1385 West 8th Avenue

Vancouver  British Columbia  V6H 3V9  Canada
Phone: 604-678-1388 Fax: 604-737-7077



Start Up

Company News
Zymeworks Announces The Successful Achievement Of A Milestone With Eli Lilly (LLY) In Bi-Specific Antibody Therapeutics Collaboration 1/19/2016 10:12:33 AM
Zymeworks And Kairos Therapeutics Enter Into Strategic Partnership And Optional Merger Agreement To Develop Antibody Drug Conjugates And Bi-Specific Antibodies 1/8/2016 11:29:45 AM
Zymeworks Banks $61.5 Million Series A 1/8/2016 7:04:23 AM
Roaring Zymeworks Inks Antibody Pact Worth $440 Million+ with GlaxoSmithKline (GSK) 12/3/2015 5:51:43 AM
Zymeworks Contracts ProBioGen AG For Bi-specific GlymaxX Antibody Cell Line Development 10/14/2015 11:19:31 AM
Zymeworks Presented With BIOTECanada Emerging Company Of The Year Gold Leaf Award 6/9/2015 10:51:26 AM
Celgene (CELG) Bets Big on Canada's Zymeworks 1/21/2015 6:17:48 AM
The Fonds de solidarité FTQ Invests $4 Million In Zymeworks In Support Of Québec’s Health Sciences Sector 12/19/2014 11:20:49 AM
Zymeworks And Merck & Co. (MRK) Extend And Expand Bi-specific Antibody Therapeutics Collaboration 12/9/2014 2:16:29 PM
Zymeworks Announces Research Collaboration With Dr. Dennis J. Slamon And University of California, Los Angeles (UCLA) 11/25/2014 9:57:00 AM